GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc - GSK

Haleon PLC

Sanofi

Investors are bracing for billions of dollars in losses due to lawsuits filed over the heartburn drug Zantac.

Zantac Lawsuits Tank Pharma Stocks As Haleon, GSK, Sanofi Issue Defense

Pfizer

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.

Drugmaker stocks slammed over Zantac lawsuit concerns

LOS ANGELES--(BUSINESS WIRE)---- $GSK #GSK--The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also called the selloff overdone.

GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.

GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation from leading drugmakers.

GSK defends Zantac ahead of trials that have cratered the stock

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

GSK PLC (LSE:GSK, NYSE:GSK) and Haleon PLC (LSE:HLN, NYSE:HLN) issued separate statements today after their stock was hit by lawsuits claiming GSK's acid indigestion drug Zantac can cause cancer.   GSK lost nearly 8% of its market value yesterday, with its share price tumbling from 1,527.2p to 1,409.5p, wiping billions of pounds from its £59.24bn market cap.

GSK to 'vigorously defend' itself against claims stomach acid drug Zantac causes cancer

European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains.

European shares eke out gains at open as healthcare stocks rebound

A wave of litigation is coming into view.

Why GSK Is So Deep in the Red Today

Source: Willy Barton / Shutterstock.com Investors in GSK (NYSE: GSK ) stock, Pfizer (NYSE: PFE ) and Sanofi (NASDAQ: SNY ) are all feeling the heat today. Reportedly, they're concerned about legal possibilities surrounding Zantac, a heartburn drug removed from stores in 2019 due to safety concerns.

GSK, PFE, SNY Stocks Fall on Zantac Litigation

GSK PLC (LSE:GSK, NYSE:GSK) and Haleon PLC (LSE:HLN, NYSE:HLN) were the biggest FTSE 100 fallers on Thursday amid investor concerns surrounding US lawsuits over heartburn drug, which was withdrawn from the market in 2019 on cancer fears. Shares in pharma giant GSK, which specialises in infectious diseases, HIV, oncology and immunology, sunk 8.8% to 1,419p, while its recent consumer healthcare spinoff declined 7.7% to 258p on the news.

GSK and Haleon given headache by cancer-linked heartburn drug

Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms appeared first on Investor's Business Daily.

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms

European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22.

GSK, Sanofi and Haleon slump on worries over Zantac litigation

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus

ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide

GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide

GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.

Could GSK's Haleon Spinoff Backfire?

GSK or Haleon: Which Is the Real Beneficiary of This Spinoff?

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.

GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and

GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis

Early Wednesday, GSK stock dipped slightly despite beating second-quarter expectations and raising its full-year guidance. The post Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell appeared first on Investor's Business Daily.

Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell

Best Buy

Brookfield Renewable Partners

Blackstone Group

Dominion Energy

JPMorgan Chase & Co

McDonald's

With the stock market still volatile and in a bottoming process, it's a good time to find dividend stocks to buy on the dip. As the old saying goes, dividend stocks “pay you to wait.

7 Dividend Stocks to Buy on the Dip

The pharmaceutical company says it expects adjusted operating profit for the year to rise 13% to 15%, higher than previous guidance of 12% to 14%.

GSK Raises Full-Year Forecast

GSK PLC (LSE:GSK, NYSE:GSK) has raised its full-year guidance after a bumper second quarter that exceeded City expectations. The drugs giant now expects 2022 sales to increase by 6% to 8%, compared with a previous forecast of 5% to 7%, while the range for core operating profit increases by a percentage point to 13% to 15%.

GSK raises full-year guidance after bumper second quarter; shingles drug the star performer

News for GlaxoSmithKline Stock (GSK)